Fig. 4From: Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysisRisk ratio of developing an irAE with ipilimumab at 10 mg/kg compared with 3 mg/kg for global irAEs all grade (a) and high grade (b)Back to article page